Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA-002 in High-grade Non-muscle Invasive Bladder Cancer
NCT05085977Phase 1Completed
- Sponsor
- Protara Therapeutics
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Cell Therapies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of TARA-002 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Protara Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities, Maximum Tolerated Dose and 1 more. Started Mar 2022; status: completed.
02
Drugs
TARA-002
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05085977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085977.